Class / Patent application number | Description | Number of patent applications / Date published |
514382000 | Additional chalcogen containing hetero ring | 36 |
20080242713 | Novel 5-cyano-prostacyclin derivatives as agents for the treatment of autoimmune diseases - This invention is directed to compounds of formula (I): | 10-02-2008 |
20080242714 | Novel 5-cyano-prostacyclin derivatives as agents for the treatment of influenza a viral infection - This invention is directed to compounds of formula (I): | 10-02-2008 |
20080300289 | Glucagon Receptor Antagonists, Preparation and Therapeutic Uses - The present invention discloses novel compounds of Formula I, or pharmaceutically acceptable salts thereof, which have glucagon receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I as well as methods of using them to treat diabetic and other glucagon related metabolic disorders, and the like. | 12-04-2008 |
20090042962 | Therapeutic Agent for Keratoconjunctival Disorder - An object of the present invention is to research a therapeutic agent for a keratoconjunctival disorder. A compound represented by the following general formula (1) or a salt thereof exhibits an excellent improving effect on corneal disorder models, and therefore is useful as a therapeutic agent for a keratoconjunctival disorder such as dry eyes, corneal ulcer, keratitis or conjunctivitis. In the formula, the ring Y represents a substituted or unsubstituted nitrogen-containing heterocyclic ring; R | 02-12-2009 |
20090069397 | DEUTERIUM-ENRICHED OLMESARTAN - The present application describes deuterium-enriched olmesartan, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 03-12-2009 |
20090082411 | Pharmaceutical for prevention or treatment of bone metabolic disease - A method for treating a bone metabolic disease by administering to a human a pharmacologically effective amount of an angiotensin II receptor antagonist which is a compound of the following formula (I), a pharmacologically acceptable salt thereof or a pharmacologically acceptable ester thereof: | 03-26-2009 |
20090131492 | Indole derivatives as CFTR modulators - Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention. | 05-21-2009 |
20090176849 | Process for the preparation of 2-alkyl-1-((2'-substituted-biphenyl-4-yl) Methyl)-imidazole, dihydroimidazole or benzimidazloe derivatives - The invention relates to a new process for the preparation of sartans 2-butyl-3-[[2′-[1-(triphenylmethyl)-1H-tetrazol-5-yl][1,1′-biphenyl]-4-yl]methyl]-1,3-diazaspiro[4.4]non-1-en-4-one is disclosed, which proceeds via novel intermediate, 4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]phenylboronic acid (Formula (II)) or its analogs. Compound (II) reacts with 5-(2-bromophenyl)-1-(triphenylmethyl)-1H-tetrazole (III) in the presence of catalyst, using conditions of Suzuki reaction, to give trityl irbesartan (I), whereas analogs to compound (II) may give candesartan, valsartan, telmisartan, losartan and olmesartan. | 07-09-2009 |
20090209603 | Olmesartan medoxomil with reduced levels of impurities - The present invention provides the preparation of olmesartan medoxomil containing less than about 0.1% of one or more of the impurities OLM-Me, OLM-Cl, and OLM-eliminate. | 08-20-2009 |
20090247596 | THIOPHENECARBOXAMIDE DERIVATIVES AS EP4 RECEPTOR LIGANDS - The invention is directed to thiophenecarboxamide derivatives of formulae I and II as EP4 receptor ligands, antagonists or agonists, useful for the treatment of EP4 mediated diseases or conditions, such as acute and chronic pain, osteoarthritis, rheumatoid arthritis, cancer and glaucoma. Pharmaceutical compositions and methods of use are also included. (Formulas I and II). | 10-01-2009 |
20090326026 | Tricyclic Compounds Useful as Angiotensin II Agonists - There is provided compounds of formula (I), wherein X | 12-31-2009 |
20100029735 | THERAPEUTIC COMPOUNDS - Disclosed herein is a compound of the formula. Therapeutic methods, compositions, and medicaments for the treatment of glaucoma or ocular hypertension related thereto are also disclosed. | 02-04-2010 |
20100137388 | Therapeutic Pro-Antibiotic Agents and Methods of Use Thereof - The present invention provides for therapies characterized in part by co-administration or combination of antibiotic agents with medicinal compositions comprising as the pro-antibiotic active ingredient either a compound represented by a formula [I] or a pharmaceutically acceptable composite thereof; [wherein X represents oxygen, sulfur, NH, or N-alkyl; R | 06-03-2010 |
20110065765 | ANGIOTENSIN II RECEPTOR ANTAGONISTS - A compound having the structure | 03-17-2011 |
20110077279 | ANGIOTENSIN II RECEPTOR ANTAGONISTS - A compound having the structure | 03-31-2011 |
20110136881 | Novel Pyrrole Inhibitors of S-Nitrosoglutathione Reductase as Therapeutic Agents - The present invention is directed to inhibitors of S-nitrosoglutathione reductase (GSNOR), pharmaceutical compositions comprising such GSNOR inhibitors, and methods of making and using the same. | 06-09-2011 |
20110144170 | Fc RECEPTOR MODULATING COMPOUNDS AND COMPOSITIONS - The present invention provides compounds capable of binding to an Fc receptor and modulating Fc receptor activity comprising a core lipophilic group in the form of an Aryl zing substituted with a group rich in p-electrons. The invention further provides for a method of treating an autoimmune disease involving Fc receptor activity using such compounds. A method for obtaining a compound which modulates Fc receptor activity is also provided, the method comprising: (a) providing or designing compounds having structural characteristics to fit in the groove of the FcγRIIa structure; and (b) screening the compounds for modulating activity on the Fc receptor. | 06-16-2011 |
20110263666 | PROCESS FOR THE PREPARATION OR PURIFICATION OF OLMESARTAN MEDOXOMIL - The present invention relates to a process for the preparation and purification of olmesartan medoxomil hydrohalide salts and optionally converting them to olmesartan medoxomil. The invention also relates to products obtainable by the process of the invention, to pharmaceutical compositions comprising the products and to their use in medicine, particularly to treat hypertension. | 10-27-2011 |
20110275683 | Selenophene and Selenazole Carboxylic Acid Derivatives - Derivatives of selenophene and selenazole heterocycles are disclosed. The compounds are useful as inhibitors of D-amino acid oxidase (DAO) and in the treatment of neurodegenerative and psychiatric diseases and disorders. | 11-10-2011 |
20120046327 | METHOD FOR INHIBITING THE INDUCTION AND FORMATION OF OSTEOCLASTS - Methods for (i) inhibiting the induction and formation of osteoclasts, (ii) inhibiting RANKL expression in osteoblasts, (ii) inhibiting the activation of osteoclasts and (iv) inhibiting a decrease in bone density by administering to a warm-blooded animal in need thereof a pharmacologically effective amount of a compound selected from the group consisting of olmesartan and olmesartan medoxomil, a pharmacologically acceptable salt thereof or a pharmacologically acceptable ester thereof. | 02-23-2012 |
20120071529 | Tetrazole Compounds Which Selectively Modulate The CB2 Receptor - Compounds of formula (I) | 03-22-2012 |
20120149743 | Selenophene and Selenazole Carboxylic Acid Derivatives - Derivatives of selenophene and selenazole heterocycles are disclosed. The compounds are useful as inhibitors of D-amino acid oxidase (DAO) and in the treatment of neurodegenerative and psychiatric diseases and disorders. | 06-14-2012 |
20120238608 | ANGIOTENSIN II RECEPTOR ANTAGONISTS - A compound having the structure wherein R is, for example, Y is selected from the group consisting of 1) R5, 2) —C(R1R2) (C(R3R4))0-1Y1R5, and 3) —C(R1R2)—O—Y1R5; R1, R2, R3 and R4 are independently selected from the group consisting of hydrogen and C1-4 alkyl; R5 is; Y1 is selected from the group consisting of C(O)—O— and P(O)(OR6)—O—; and R6 is hydrogen or CH3, or a pharmaceutically acceptable salt thereof, and methods of using the compounds for treating hypertension. | 09-20-2012 |
20120302614 | METHOD FOR IMPROVING CEREBRAL CIRCULATION OR TREATING A CEREBRAL BLOOD FLOW DISORDER - A method for improving cerebral circulation or treating a cerebral blood flow disorder, comprising administering a pharmacologically effective amount of an angiotensin II receptor blocker to a human. | 11-29-2012 |
20130072530 | NOVEL EP4 AGONIST - Provided is a compound represented by the formula (1): | 03-21-2013 |
20130253024 | Novel Pyrrole Inhibitors of S-Nitrosoglutathione Reductase as Therapeutic Agents - The present invention is directed to inhibitors of S-nitrosoglutathione reductase (GSNOR), pharmaceutical compositions comprising such GSNOR inhibitors, and methods of making and using the same. | 09-26-2013 |
20140128441 | NOVEL EP4 AGONIST - Provided is a compound represented by the formula (1): | 05-08-2014 |
20140194481 | Novel Pyrrole Inhibitors of S-Nitrosoglutathione Reductase as Therapeutic Agents - The present invention is directed to inhibitors of S-nitrosoglutathione reductase (GSNOR), pharmaceutical compositions comprising such GSNOR inhibitors, and methods of making and using the same. | 07-10-2014 |
20140235683 | Compositions and Methods for the Treatment of Norovirus Infection - Compositions and methods for the treatment of norovirus infection are disclosed. | 08-21-2014 |
20140309266 | ANTIMICROBIAL/ADJUVANT COMPOUNDS AND METHODS - Among other things, in general, antimicrobial and/or adjuvant compounds are provided according to Formula Ia: (Ia) in which E and R1-11 have the meanings described herein; and prodrugs and pharmaceutically acceptable salts thereof. Other formulae and methods of use are also provided. | 10-16-2014 |
20150018400 | TREATMENT OF INFLAMMATORY BOWEL DISEASE - Disclosed herein is a method comprising administering a compound to a mammal suffering from an inflammatory bowel disease for the treatment of said disease, said compound having a structure according to Formula I | 01-15-2015 |
20150018401 | NOVEL EP4 AGONIST - Provided is a compound represented by the formula (1): | 01-15-2015 |
20150148388 | CHEMICAL COMPOSITION - The present invention is directed to stable chemical compositions and dosage forms that comprise nebivolol and valsartan and which achieve therapeutically effective plasma levels of both actives in hypertensive patients following administration, as well as to methods of lowering blood pressure and treating hypertension using such compositions and dosage forms. | 05-28-2015 |
20150148389 | Methods for Treating or Preventing Brain Infections - The invention is directed to methods of treating organ specific infections in a host organism by administering compounds that target host receptors and/or host cellular signaling molecules to prevent a pathogen from infecting the organ. For example, the administration of a compound to prevent a pathogen from crossing the blood-brain barrier to prevent a brain infection. | 05-28-2015 |
20160022639 | FIXED DOSE COMBINATION FOR PAIN RELIEF WITHOUT EDEMA - Compositions and methods for individualized therapy of pain using a non-steroidal anti-inflammatory drug (NSAID) and an anti-hypertensive without inducing intolerable edema. Said methods comprise basing NSAID/anti-hypertensive dose on each patient's pharmacokinetic response to said NSAID. | 01-28-2016 |
20160176856 | Compositions and Methods for the Treatment of Norovirus Infection | 06-23-2016 |